2,6,3',5'-四羟基二苯乙烯
2,6,3',5'-四羟基二苯乙烯 性质
| 熔点 | 271°C(lit.) |
|---|---|
| 沸点 | 540.8±30.0 °C(Predicted) |
| 密度 | 1.468±0.06 g/cm3(Predicted) |
| 储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
| 溶解度 | 溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。 |
| 形态 | 粉末晶体 |
| 酸度系数(pKa) | 9.06±0.40(Predicted) |
| 颜色 | 白色至浅黄色至浅橙色 |
| 最大波长(λmax) | 337nm(EtOH)(lit.) |
| CAS 数据库 | 86361-55-9 |
2,6,3',5'-四羟基二苯乙烯 用途与合成方法
|
COX-1 0.78 μM (IC 50 ) |
Tyrosinase 4.5 μM (IC 50 ) |
HDAC
|
The antiproliferative activities of Gnetol are tested in HCT-116, Hep-G2, MDA-MB-231, and PC-3 cell lines by measuring cell viability after treatment with 4.1 μM, 40.9 μM, 204.7 μM, 409.4 μM, and 1023.6 μM. Gnetol shows concentration-dependent reductions in cell viability in cancer cell lines with greatest activity in colorectal cancer.
Gnetol at 200 µg/mL significantly offers the highest protection of 54.3% against the toxicant. A lower dose of Gnetol (50 µg/mL) also shields the cell line from the toxic effects of CCl4.
The ligand molecule TGF-β and PPARα protein show that Gnetol has the binding affinity of 7.0 and 8.4, respectively.
Male Sprague-Dawley rats were cannulated and dosed either intravenously with Gnetol (10 μg/kg) or orally (100 mg/kg). After oral and intravenous administration, Gnetol is detected in both serum and urine as the parent compound and as a glucuronidated metabolite. The bioavailability of Gnetol is determined to be 6%. Gnetol is rapidly glucuronidated and is excreted in urine and via nonrenal routes.
Pretreatment of Male NIH Swiss mice (20-35 g) with Gnetol (50mg/kg, SC) is able to increase the latency period to response in analgesia models.
2,6,3',5'-四羟基二苯乙烯 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-126052 | 1 mg | 900 | ||
| 2024-11-08 | HY-126052 | 2,6,3',5'-四羟基二苯乙烯 | 86361-55-9 | 5mg | 1580 |
